NCT05732272View on ClinicalTrials.gov

Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment

PHASE3RecruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

March 31, 2027

Conditions
Smoking Cessation
Interventions
DRUG

Bupropion

150 mg once daily for 3 days, then twice daily for the remainder of the treatment phase.

Trial Locations (1)

64130

RECRUITING

University of Kansas Medical Center, Kansas City

All Listed Sponsors
lead

University of Kansas Medical Center

OTHER